Zymeworks Inc.
Financial highlights
| Metric | FY 12/31/25 | FY 12/31/24 | FY 12/31/23 | FY 12/31/22 | FY 12/31/21 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $106.0M | $76.3M | $76.0M | $412.5M | $26.7M |
| Research and development | $137.0M | $134.6M | $143.6M | $208.6M | $199.8M |
| Operating income | -$92.5M | -$137.1M | -$138.1M | $130.5M | -$215.6M |
| Pretax income | -$79.8M | -$116.6M | -$119.2M | $135.2M | -$212.4M |
| Income tax expense | $1.4M | $6.1M | -$568,000 | $10.9M | -$516,000 |
| Net income | -$81.1M | -$122.7M | -$118.7M | $124.3M | -$211.8M |
| Balance Sheet | |||||
| Cash and equivalents | $41.2M | $66.1M | $157.6M | $400.9M | $201.9M |
| Current assets | $248.8M | $300.5M | $412.9M | $544.7M | $288.2M |
| Total assets | $346.5M | $463.1M | $580.9M | $648.7M | $389.1M |
| Current liabilities | $42.3M | $88.3M | $55.8M | $95.6M | $71.9M |
| Total liabilities | $78.0M | $124.3M | $116.1M | $155.8M | $140.0M |
| Stockholders' equity | $268.5M | $338.8M | $464.8M | $493.0M | $249.1M |
| Cash Flow Statement | |||||
| Cash from operations | -$33.0M | -$110.1M | -$118.3M | $144.1M | -$192.5M |
| Depreciation and amortization | $3.7M | $4.2M | $7.5M | $6.2M | $3.7M |
| Stock-based compensation | $28.0M | $17.8M | $8.1M | $4.0M | $10.8M |
| Capital expenditure | $1.5M | $2.0M | $2.5M | $8.2M | $12.4M |
| Free cash flow | -$34.5M | -$112.0M | -$120.8M | $136.0M | -$204.9M |
| Share repurchases | $41.7M | $30.1M | $0 | $0 | — |
| Impairments | $0 | $0 | $0 | $0 | — |
Shares outstanding 73.0M · Free float 55.8%
Annual filing data through FY ended December 31, 2025; float as of July 16, 2026.